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Following fetal or neonatal gene transfer in mice and other species immune tolerance of the transgenic protein is frequently
observed; however the underlying mechanisms remain largely undefined. In this study fetal and neonatal BALB/c mice received
adenovirus vector to deliver human factor IX (hFIX) cDNA. The long-term tolerance of hFIX was robust in the face of immune
challenge with hFIX protein and adjuvant but was eliminated by simultaneous administration of anti-CD25+ antibody. Naive
irradiated BALB/cmice which had received lymphocytes from donors immunised with hFIX developed anti-hFIX antibodies upon
immune challenge. Cotransplantation with CD4+CD25+ cells isolated from neonatally tolerized donors decreased the antibody
response. In contrast, cotransplantation with CD4+CD25− cells isolated from the same donors increased the antibody response.
These data provide evidence that immune tolerance following perinatal gene transfer is maintained by a CD4+CD25+ regulatory
population.
1. Introduction
Fetal or neonatal gene transfer has been proposed as a
potential therapeutic strategy with several advantages over
adult gene transfer including increased likelihood of immune
tolerization towards the transgenic protein [1, 2]. Absence of
immune response after fetal or neonatal gene or stem cell
delivery has been demonstrated in several studies [2–5], some
of which have provided evidence for immune tolerance. We
have previously observed prolonged expression of human
factor IX (hFIX) after adenovirus-mediated gene transfer to
fetal mice of the MF1 outbred strain. There was transient and
minimal production of anti-hFIX antibodies after immune
challenge by repeated injection of purified hFIX protein and
hFIX-adenovirus in adulthood [6].
To interrogate the immunemechanisms after fetal or neo-
natal gene transfer more extensively we used inbred BALB/c
mice. These mice were chosen since they express relatively
high levels of hFIX after neonatal retroviral gene transfer [4],
exhibit a dominant Th2 response [7], and, unlike outbred
MF1 mice, can be used for adoptive transfer experiments.
Adenovirus serotype 5 vector was used throughout.
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2. Materials and Methods
Adenoviral vectors with CMV driving human factor FIX
[6] (AdhFIX) and firefly luciferase [8] (AdLuc) genes were
prepared. Vectors were titered by 293-cell plaque assays. E16
fetal mice received intravenous injection via the vitelline
vessels [6]. P0 neonates received injections under hypother-
mic anaesthesia via the superficial temporal vein [9]. Adults
received injections via the lateral tail vein. Fetuses, neonates,
and adults received 1 × 109, 1 × 109, and 3 × 1010 vector
genomes per mouse. Citrated blood was collected for plasma
for hFIX assay and for serum for antibody analysis. Plasma
concentrations of hFIX protein were determined using the
Asserachrom FIX ELISA kit with pooled human plasma
as assay standard. Antibodies against hFIX and adenovirus
were detected as previously described [6]. Anti-CD25 IL2R
rat IgG1 antibody was produced by PC61 hybridoma cells
(American Type Culture Collection, Manassas, USA) using
a capillary cell culture system as per manufacturer’s proto-
col (CellMax Artificial Capillary Module, Cellco Inc., MD,
USA). Antibody was purified and concentrated using affinity
chromatography (Mab Trap, Amersham Biosciences UK
Limited). For vector genome quantitation, 100 ng extracted
DNAwas subjected to quantitative PCR (ABI Prism 7900HT,
Applied Biosystems Ltd., Warrington, UK) using hexon spe-
cific primers (5󸀠CGCGGTGCGGCTGGTG3󸀠 and 5󸀠TGG-
CGCATCCCATTCTCC3󸀠) normalized against a standard
curve ranging from 101 to 107 adenovirus particles. For
adoptive transfer experiments, recipients received sublethal
irradiation (400 cGy) 24 h before cell transfer and hFIX
immunization. Lymphocytes were harvested from inguinal,
caudal, and mesenteric lymph nodes and combined with
splenocytes. CD4+CD25+ and CD4+CD25− populations
were purified using magnetic beads (MACS Cell Separation,
Miltenyi Biotec, Surrey, UK). Purity was confirmed by FACS
analysis. From sensitized or naive pooled donors 3 × 107
lymphocytes were injected intravenously into recipients. 1 ×
104 or 1 × 105 CD4+CD25+ or CD4+CD25− cells were
cotransplanted; both concentrations were equally effective
for the two transplanted populations; therefore antibody
data was pooled for subsequent analysis and presentation.
Luciferase expression in organ homogenates was assayed
using the Luciferase Assay System (Promega, WI, USA)
and luminometer (Lucy1, Anthos, Germany) as previously
described [10].
3. Results
3.1. Longevity of Expression and Immune Challenge. Wemea-
sured hFIX expression and anti-hFIX antibodies following
intravascular injection of AdhFIX into fetal (𝑛 = 20), neona-
tal (𝑛 = 21) (Figure 1(a)), and adult (𝑛 = 4) (Figure 1(b))
BALB/c mice. After perinatal delivery hFIX concentrations
were greater than 2 𝜇g/mL at 48 hours but declined to
a stable concentration of approximately 50 ng/mL beyond
150 days; some mice (≈15%) lost expression. None devel-
oped significant anti-hFIX antibodies. In contrast, following
adult delivery hFIX concentrations were between 0.1 and
0.6 𝜇g/mL at 48 hours and declined to zero within 7 days.
High concentrations of anti-hFIX antibodies were detected
from day 14 onwards.
As a stronger test of immune tolerance to hFIX, adult
mice which had received AdhFIX in utero received two
subcutaneous injections (𝑛 = 9) of purified hFIX plus MPL-
TDM adjuvant (at 140 and 175 days of age) (four received
an additional challenge of AdhFIX at 275 days (Figure 1(c))
to test tolerization to vector, described below). Eight mice
showedno significant decrease in hFIX expression or increase
in anti-hFIX antibodies after each challenge; however one
mouse, which had no hFIX expression at the time of
challenge, developed high titer anti-hFIX antibodies. This
supports the observation of others that continual antigen
expression is required for maintenance of tolerance following
perinatal gene transfer [4]. All naive adult controls developed
high anti-hFIX antibody titers following challenge (𝑛 = 4,
data not shown).
3.2. Depletion of CD4+CD25+ Cells. The mechanism of
immune tolerance was investigated. Six months after fetal
AdhFIX injection, mice still expressing hFIX (range 24–
148 ng/mL) received three intravenous injections of anti-
CD25+ antibody (𝑛 = 7) to deplete CD25+ regulatory T
cells; controls received rat IgG antibody (𝑛 = 7) (1mg/mouse)
(0, 4, and 29 days). Subsequent to each antibody injection,
mice received a subcutaneous injection of a mix of hFIX
(1 g/mouse), ovalbumin (1 g/mouse), and adjuvant (Freund’s
complete adjuvant and then 2x Freund’s incomplete adju-
vant). Blood was collected 9 days after the third immune
challenge. All mice that received the anti-CD25+ antibody
developed high anti-hFIX titres unlike those that received
control rat IgG (Figure 1(e)). These results provide evidence
that CD4+CD25+ regulatory T cells contribute to maintain-
ing tolerance after perinatal gene transfer. To confirm that the
depleting antibody was antigen-specific in breaking immune
tolerance to hFIX rather than acting as a global immune
stimulus, anti-ovalbumin antibody titres were measured.
Unexpectedly, mice receiving depleting antibody developed a
reduced immune response to ovalbumin (Figure 1(f)). Since
PC61 also binds to recently activated cells, which express
the IL-2 receptor 𝛼, those reactive to ovalbumin may be
inactivated or deleted.
3.3. Adoptive Transfer Experiments. The mechanism of im-
mune tolerance was interrogated further. A cohort of mice
still expressing hFIX more than 250 days after neonatal
AdhFIX injection received three subcutaneous immunisa-
tions with hFIX and Freund’s adjuvant; immune tolerance
was confirmed by hFIX expression and absence of antibodies.
A second cohort of naive mice was sensitised by subcuta-
neous immunisation three times with hFIX and Freund’s
adjuvant. Irradiated BALB/c recipients received lymphocytes
from sensitized mice (𝑛 = 4). Alternatively recipients re-
ceived cotransplantation of sensitised lymphocytes plus
either CD4+CD25+ (𝑛 = 9) or CD4+CD25− (𝑛 = 7) lym-
phocytes from tolerized mice (𝑛 = 9). Two recipients re-
ceived whole lymphocyte population from naive donors.
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Figure 1: Measurement of concentrations of hFIX and anti-hFIX antibodies following perinatal and adult AdhFIX injection. (a)
Concentrations of hFIX (red upper graph) and anti-hFIX antibodies (black lower graph) following fetal (𝑛 = 20, small squares) and neonatal
(𝑛 = 21, large diamonds) injection of AdhFIX. (b) Concentrations of hFIX (red upper graph) and anti-hFIX antibodies (black lower graph)
following adult injection of AdhFIX. (c) Concentrations of hFIX (red upper graph) and anti-hFIX antibodies (black lower graph) in mice
injected in utero with AdhFIX. Two immune challenges with hFIX plus adjuvant and one AdhFIX were administered at 𝑡 = 140, 175, and 275
(labelled arrows). (d) Concentration of anti-adenovirus antibody in naive controls (C1-3), positive control mice which received hFIX plus
adjuvant (S1-3), andmice having received AdhFIX in utero (plotted lines). Mice having received AdhFIX in utero received immune challenges
with hFIX plus adjuvant and one AdhFIX was administered at 𝑡 = 140, 175, and 275 (labelled arrows). (e) Anti-hFIX antibodies in serially
diluted plasma of mice tolerized to hFIX by fetal AdhFIX. Mice received three injections of anti-CD25+ depleting antibody (black, closed
circles, and unbroken line) or rat IgG negative control (blue, open circles, and dotted line) simultaneously with hFIX plus ovalbumin plus
adjuvant. Nine days after the final challenge, sera were collected for analysis. (f) Anti-ovalbumin antibodies in serially diluted plasma of mice
tolerized to hFIX by fetal AdhFIX. Mice received three injections of anti-CD25+ depleting antibody (black, closed circles, and unbroken line)
or rat IgG negative control (blue, open circles, and dotted line) simultaneously with hFIX plus ovalbumin plus adjuvant. Nine days after the
final challenge, sera were collected for analysis.
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Figure 2: Adoptive transfer of regulatory cell populations, tissue distribution of vector, and transgene expression. (a) Anti-hFIX antibody
concentrations in serum diluted 1/100 following adoptive transfer of lymphocytes from hFIX-sensitised mice (black bar), cotransplantation
of sensitised cells plus CD4+CD25+ cells from neonatally tolerized mice (blue bar) or plus CD4+CD25− cells from neonatally tolerized mice
(red bar), or adoptive transfer of lymphocytes from naive donors (grey bars). Recipients underwent sublethal irradiation, adoptive transfer,
and hFIX-immunisation 24 hours later and blood collection on days 7, 17, and 24. (b) Quantitative PCR analysis of vector genome distribution
and (c) luciferase expression six weeks after neonatal injection of AdLuc.
Following subcutaneous immunisation with hFIX and Fre-
und’s adjuvant blood was collected on days 7, 17, and 24 for
anti-hFIX analysis (Figure 2(a)). At all times, recipients of
sensitised cells produced substantially more anti-hFIX anti-
body than those which had received naive cells. Importantly,
cotransplantation of CD4+CD25+ cells from tolerized mice
significantly decreased antibody production (general linear
model, Tukey pairwise comparison, 𝑃 = 0.037) whereas
cotransplantation of CD4+CD25− cells from tolerized mice
significantly increased antibody production (𝑃 = 0.040).This
provides further evidence that after perinatal gene transfer,
a CD4+CD25+ population downregulates immune reactivity
to hFIX as measured by anti-hFIX antibody production.
This cell population appears to mediate tolerance in a
greater number of gene therapy protocols than previously
anticipated. For example, CD4+CD25+ regulatory T cells
have been implicated in immune tolerance following liver
gene transfer using adenoassociated virus vector [11]. Since
cotransplantation of CD4+CD25− cells did not abolish anti-
body development in recipients, the role of other regulatory
cell populations or deletional tolerance cannot be ruled
out. Indeed, others provide evidence for deletional tolerance
Journal of Immunology Research 5
following injection of hFIX retrovirus into neonatal mice
[12]. Nevertheless, recently, Gaensler and colleagues provided
elegant demonstration for a role of CD4+CD25+ regulatory
T cells in maintaining immune tolerance following neonatal
intraperitoneal injection of adenoassociated virus vector
[13].
3.4. Biodistribution of Vector Genomes and Gene Expres-
sion. Six to twelve weeks after neonatal AdLuc, luciferase
expression and vector genomes were quantitated in different
organs. Although fewer vector genomes were present in
spleen (19,880 ± 4600 vg/100 ng DNA) and thymus (45,072 ±
14,693 vg/100 ng DNA) compared with those in other tissues
(Figure 2(b)) significant luciferase expression was detected
(Student’s 𝑡-test, 𝑃 < 0.01) (Figure 2(c)). Therefore, a role for
central tolerance cannot be ruled out.
3.5. Evidence for Tolerization to Vector. Detection of anti-
adenovirus antibodies was performed on four adult mice
from the experiment shown in Figure 1(d) (i.e., they received
AdhFIX in utero, two challenges of hFIX plus adjuvant on
140 and 175 days and AdhFIX on 275 days). Only one of
these mice developed anti-adenovirus antibodies after adult
AdhFIX challenge as did all the naive adult mice receiving
AdhFIX challenge (S1-3) whereas antibodies remained unde-
tectable in the remaining three, like in the nonchallenged
controls (C1-3) (Figure 1(d)). This provides evidence for
immune tolerization to vector components. This may be
attributable to the use of first E1/E3-deleted adenovirus which
might lead to continuous expression of small amounts of viral
proteins, particularly since vector genomes can be detected
in thymuses from adult mice injected neonatally with AdLuc
(Figure 2(b)). Alternatively, it may arise from cotolerization
from simultaneous initial exposure to hFIX and adenovirus
antigens.
4. Discussion
Lifelong gene expression of various transgenes in mice has
been achieved following perinatal delivery of vectors derived
from adenovirus [6], gamma retrovirus [4], lentivirus [14],
and adenoassociated virus [15, 16]. These studies have led
to improvements in the vector and expression cassette and
providemotivation for childhood or even infant gene therapy
for early onset genetic diseases. However understanding of
the immune response to perinatal gene therapy remains poor.
Here, we provide evidence for a contribution of regulatory
tolerance to transgenic proteins following fetal and neonatal
delivery in BALB/c mice. This supports recent observations
of regulatory tolerance following AAV vector delivery [13].
One unexpected finding was evidence for immune tolerance
to vector components. Although this might permit multiple
postnatal administrations of the same vector, it might also
render the recipient vulnerable to infection by the archetypal
virus, clearly an undesirable outcome. One possible explana-
tion for tolerization is residual and continuous expression of
viral proteins.This provides strong justification for removal of
all viral sequences from vectors designed for long-term treat-
ment of genetic diseases. For example, third generation HIV-
based vectors contain approximately 1.8 kb of viral genetic
material. This situation contrasts with recent observations
by Carlon and colleagues, where perinatal delivery of AAV
vector to murine airways benefitted from immune ignorance
(rather than tolerance) to the capsid proteins, permitting a
second administration at a later time point [17].
In these studies, it is important to consider the develop-
mental stage of the mouse immune system in late gestation
relative to the immune system of the fetal and newborn
human. Holladay and Smialowicz have provided an excellent
comparison of the developing mouse and human immune
system. By the end of the third trimester, the human B cells
express surface IgG, lymphocyte precursors are present in
the thymus, thymocytes subsequently become responsive to
mitogens, and functional natural killer cells arise. In contrast,
in the mouse, lymphocyte precursors in the thymus are
detected at around 11 days of gestation whereas B cell sur-
face IgG and thymocytes responsiveness to mitogen occurs
around 17 days of gestation and NK cells arise after birth [18].
In humans, mature peripheral a/b T cells first appear towards
the end of the first trimester whereas inmice they only appear
at the end of gestation [19]. However the situation is more
complex, in that human serum IgM and IgG concentrations
do not reach adult concentrations until 1-2 years of age and
4–6 years of age, respectively. Moreover before 2 years of
age, babies fail to mount humoral immune responses to some
antigens [18]. An additional complication is that, recently, it
has been shown that in humans, as in mice and birds, the
immune system is layered, whereby hematopoiesis occurs in
waves, specifically an early one which gives rise to fetal T cells
and a later one that gives rise to different adult T cells. The
fetal and adult T cells possess different functional properties
and gene expression patterns [20].
BALB/c mice produce relatively small litters and fre-
quently cannibalise their litters following maternal surgery.
For reasons of cost and to minimise animal wastage we
switched from fetal to neonatal gene transfer for adoptive T
cell transfer experiments as neonatal death following gene
transfer is very rare. Nevertheless it is important to recognise
that both qualitative and quantitative differences in immune
function between E16 fetal and P0 newborn mouse exist.
Over the course of the studywe switched fromMPL-TDM
adjuvant to Freund’s adjuvant. MPL-TDM is considered to
pose less of a risk of abscess formation and is therefore a better
choice when complying with the 3Rs principle of refining
experiments to minimise animal pain and distress. However
we chose to use Freund’s adjuvant for experiments involving
regulatory T cell depletion and adoptive T cell transfer, as
Freund’s adjuvant was considered likely to provide the most
potent challenge [21].
Ex vivo luciferase expression correlated poorly with vec-
tor copy number. This may be explained by the observation
that hemoglobin interferes substantially with ex vivo lumi-
nometry. This is particularly apparent in the spleen which
retains a particularly high concentration of red blood cells
and hemoglobin even when perfused [22]. An additional
explanation may be that the CMV promoter which drives
6 Journal of Immunology Research
luciferase expression in this vector may vary in activity in
different tissue types.
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